Undervalued liquidation case

(Full access for Lifetime Members only)

Undervalued liquidation case

23 April 2024

What readers said about this report

If the efficient market theory held true, this investment case wouldn't exist.

There is literally money laying on the streets, based on everything that is known now. A couple of very smart investors have spotted just that and taken control of the company featured in this report.

After many years of shareholders getting screwed by a less than savoury management, a line will now be drawn under this company's past. All assets – primarily real estate – will be sold, and the proceeds paid out to shareholders. An interesting litigation case is thrown in for good measure, whose potential proceeds are currently valued at zero.

A word of warning, though: this London-listed stock is a micro-cap. With a free float not even worth USD 20m, it has very limited trading activity. While sometimes, large blocks do come onto the market, it could prove difficult to get significant exposure.

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

|  What readers said about this report

Hung-Wah C.
April 2024

I liked your write up on (company name hidden by Undervalued-Shares.com).

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.